QIAGEN price target raised to $26 from $20 at RW Baird Baird raised its price target on QIAGEN following better than expected Q4 results. The firm cited higher guidance, tangible drivers of organic growth, and cash available for accretive use. Shares are Outperform rated.
QIAGEN sees FY15 adjusted EPS $1.16-1.18, consensus $1.10 Sees FY15 adjusted net sales to rise approximately 4% CER in 2015, as growth of about 7-8% CER in the core portfolio exceeds the adverse impact of approximately 3-4 percentage points from lower U.S. HPV sales. FY15 revenue consensus $1.32B.